Contineum Therapeutics, Inc. Class A Common Stock (CTNM) 10-Q 6 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 01, 2024
Document Information [Line Items]
Entity Central Index Key	0001855175
Entity Registrant Name	Contineum Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-42001
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-1467257
Entity Address, Address Line One	3565 General Atomics Court, Suite 200
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	333-5280
Title of 12(b) Security	Class A Common Stock, $0.001 par value per share
Trading Symbol	CTNM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		6,729,172
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		19,048,621

Condensed Balance Sheets (Curre

Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 40,891	$ 15,526
Marketable securities	173,020	109,664
Prepaid expenses and other current assets	1,232	2,516
Total current assets	215,143	127,706
Property and equipment, net	888	678
Other long-term assets	3	1,283
Operating lease right-of-use assets	0	719
Total assets	216,034	130,386
Current liabilities:
Accounts payable	1,397	635
Accrued expenses	3,798	4,385
Current portion of operating lease liabilities	611	464
Total current liabilities	5,806	5,484
Other long-term liabilities	0	110
Operating lease liabilities, net of current portion	0	108
Total liabilities	5,806	5,702
Convertible preferred stock, $0.001 par value; no shares authorized, issued, or outstanding at September 30, 2024; authorized shares—16,940,594 at December 31, 2023; issued and outstanding shares—15,906,236 shares at December 31, 2023	0	192,620
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; authorized shares—10,000,000 at September 30, 2024; no shares issued or outstanding at September 30, 2024; no shares authorized, issued, or outstanding at December 31, 2023	0	0
Additional paid-in-capital	312,478	7,098
Accumulated deficit	(102,837)	(75,144)
Accumulated other comprehensive income	561	108
Total stockholders' equity (deficit)	210,228	(67,936)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	216,034	130,386
Common Class A [Member]
Stockholders' equity (deficit):
Common stock	19	2
Common Class B [Member]
Stockholders' equity (deficit):
Common stock	$ 7	$ 0

Condensed Balance Sheets (Cur_2

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, authorized (in shares)	0	16,940,594
Convertible preferred stock, issued (in shares)	0	15,906,236
Convertible preferred stock, outstanding (in shares)	0	15,906,236
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common Class A [Member]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	200,000,000	39,630,511
Common stock, issued (in shares)	19,006,904	2,349,554
Common stock, outstanding (in shares)	19,006,904	2,349,554
Common Class B [Member]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	20,000,000	0
Common stock, issued (in shares)	6,729,172	0
Common stock, outstanding (in shares)	6,729,172	0

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
License revenue		$ 0	$ 0	$ 0	$ 50,000
Operating expenses:
Research and development		9,728	6,499	25,407	19,591
General and administrative		3,246	1,570	8,440	4,656
Total operating expenses		12,974	8,069	33,847	24,247
Income (loss) from operations		(12,974)	(8,069)	(33,847)	25,753
Other income (expense):
Interest income		2,741	1,736	6,377	2,816
Interest expense		0	0	0	(208)
Change in fair value of warrant liability		0	0	(107)	2
Change in fair value of investor rights and obligations liability		0	0	0	2,867
Other expense, net		(34)	(36)	(116)	(130)
Total other income		2,707	1,700	6,154	5,347
Income (loss) before income taxes		(10,267)	(6,369)	(27,693)	31,100
Provision for (benefit from) income taxes		0	(118)	0	611
Net income (loss)		(10,267)	(6,251)	(27,693)	30,489
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities		688	(24)	453	(13)
Comprehensive income (loss)		(9,579)	(6,275)	(27,240)	30,476
Net income (loss) attributable to common stockholders, basic		(10,267)	(6,251)	(27,693)	4,340
Net income (loss) attributable to common stockholders, diluted		$ (10,267)	$ (6,251)	$ (27,693)	$ 1,471
Net income (loss) per share, basic (a) (in dollars per share)	[1]	$ (0.4)	$ (2.69)	$ (1.61)	$ 1.89
Net income (loss) per share, diluted (a) (in dollars per share)	[1]	$ (0.4)	$ (2.69)	$ (1.61)	$ 0.43
Weighted-average shares of common stock outstanding, basic (in shares)		25,730,014	2,324,588	17,182,865	2,298,175
Weighted-average shares of common stock outstanding, diluted (in shares)		25,730,014	2,324,588	17,182,865	3,445,978
[1]Basic and diluted per share amounts are the same for Class A and Class B shares.

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Convertible Preferred Stock, Temporary Equity [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	11,889,674	2,259,734
Balance at Dec. 31, 2022	$ 132,482	$ 2	$ 4,726	$ (76)	$ (97,864)	$ (93,212)
Exercise of stock options (in shares)	0	7,146
Exercise of stock options	$ 0	$ 0	8	0	0	8
Stock-based compensation	0	0	494	0		494
Net income (loss)	0	0	0	0	(4,824)	(4,824)
Unrealized gain (loss) on marketable securities	$ 0	$ 0	0	67	0	67
Vesting of shares of common stock subject to repurchase (in shares)		5,245
Vesting of shares of common stock subject to repurchase			5			5
Balance (in shares) at Mar. 31, 2023	11,889,674	2,272,126
Balance at Mar. 31, 2023	$ 132,482	$ 2	5,233	(9)	(102,688)	(97,462)
Balance (in shares) at Dec. 31, 2022	11,889,674	2,259,734
Balance at Dec. 31, 2022	$ 132,482	$ 2	4,726	(76)	(97,864)	(93,212)
Net income (loss)						30,489
Unrealized gain (loss) on marketable securities						(13)
Balance (in shares) at Sep. 30, 2023	15,906,236	2,332,198
Balance at Sep. 30, 2023	$ 192,620	$ 2	6,317	(89)	(67,375)	(61,145)
Balance (in shares) at Mar. 31, 2023	11,889,674	2,272,126
Balance at Mar. 31, 2023	$ 132,482	$ 2	5,233	(9)	(102,688)	(97,462)
Exercise of stock options (in shares)	0	36,715
Exercise of stock options	$ 0	$ 0	47	0	0	47
Stock-based compensation	0	0	489	0		489
Net income (loss)	0	0	0	0	41,564	41,564
Unrealized gain (loss) on marketable securities	$ 0	$ 0	0	(56)	0	(56)
Issuance of stock, net of issuance costs (in shares)	3,333,239	0
Issuance of stock, net of issuance costs	$ 49,896	$ 0	0	0	0	0
Vesting of shares of common stock subject to repurchase (in shares)		14,584
Vesting of shares of common stock subject to repurchase			14			14
Repurchase of stock options (in shares)	0	(2,680)
Repurchase of stock options	$ 0	$ 0	(28)	0	0	(28)
Balance (in shares) at Jun. 30, 2023	15,222,913	2,320,744
Balance at Jun. 30, 2023	$ 182,378	$ 2	5,755	(65)	(61,124)	(55,432)
Exercise of stock options (in shares)	0	9,927
Exercise of stock options	$ 0	$ 0	83	0	0	83
Stock-based compensation	0	0	477	0		477
Net income (loss)	0	0	0	0	(6,251)	(6,251)
Unrealized gain (loss) on marketable securities	$ 0	$ 0	0	(24)	0	(24)
Issuance of stock, net of issuance costs (in shares)	683,323	0
Issuance of stock, net of issuance costs	$ 10,241	$ 0	0	0	0	0
Vesting of shares of common stock subject to repurchase (in shares)		1,528
Vesting of shares of common stock subject to repurchase			2			2
Balance (in shares) at Sep. 30, 2023	15,906,236	2,332,198
Balance at Sep. 30, 2023	$ 192,620	$ 2	6,317	(89)	(67,375)	(61,145)
Balance (in shares) at Dec. 31, 2023	15,906,236	2,349,554
Balance at Dec. 31, 2023	$ 192,620	$ 2	7,098	108	(75,144)	(67,936)
Exercise of stock options (in shares)	0	34,872
Exercise of stock options	$ 0	$ 0	122	0	0	122
Stock-based compensation	0	0	768	0		768
Net income (loss)	0	0	0	0	(8,417)	(8,417)
Unrealized gain (loss) on marketable securities	$ 0	$ 0	0	(166)	0	(166)
Balance (in shares) at Mar. 31, 2024	15,906,236	2,384,426
Balance at Mar. 31, 2024	$ 192,620	$ 2	7,988	(58)	(83,561)	(75,629)
Balance (in shares) at Dec. 31, 2023	15,906,236	2,349,554
Balance at Dec. 31, 2023	$ 192,620	$ 2	7,098	108	(75,144)	$ (67,936)
Exercise of stock options (in shares)						56,609
Net income (loss)						$ (27,693)
Unrealized gain (loss) on marketable securities						453
Balance (in shares) at Sep. 30, 2024	0	25,736,076
Balance at Sep. 30, 2024	$ 0	$ 26	312,478	561	(102,837)	210,228
Balance (in shares) at Mar. 31, 2024	15,906,236	2,384,426
Balance at Mar. 31, 2024	$ 192,620	$ 2	7,988	(58)	(83,561)	(75,629)
Exercise of stock options (in shares)	0	8,932
Exercise of stock options	$ 0	$ 0	13	0	0	13
Stock-based compensation	0	0	1,494	0		1,494
Net income (loss)	0	0	0	0	(9,009)	(9,009)
Unrealized gain (loss) on marketable securities	$ 0	$ 0	0	(69)	0	(69)
Issuance of stock, net of issuance costs (in shares)	0	7,423,682
Issuance of stock, net of issuance costs	$ 0	$ 7	107,860	0	0	107,867
Conversion of convertible preferred stock to common stock upon initial public offering (in shares)	(15,906,236)	15,906,236
Conversion of convertible preferred stock to common stock upon initial public offering	$ (192,620)	$ 17	192,603	0	0	192,620
Reclassification of warrants from liability to equity	$ 0	$ 0	216	0	0	216
Balance (in shares) at Jun. 30, 2024	0	25,723,276
Balance at Jun. 30, 2024	$ 0	$ 26	310,174	(127)	(92,570)	217,503
Exercise of stock options (in shares)	0	12,800
Exercise of stock options	$ 0	$ 0	13	0	0	13
Stock-based compensation	0	0	2,291	0		2,291
Net income (loss)	0	0	0	0	(10,267)	(10,267)
Unrealized gain (loss) on marketable securities	$ 0	$ 0	0	688	0	688
Balance (in shares) at Sep. 30, 2024	0	25,736,076
Balance at Sep. 30, 2024	$ 0	$ 26	$ 312,478	$ 561	$ (102,837)	$ 210,228

Condensed Statements of Conve_2

Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Sep. 30, 2023
Issuance costs	$ 10,912	$ 7

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net income (loss)	$ (27,693)	$ 30,489
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:
Depreciation and amortization	183	158
Non-cash operating lease expense	719	701
Stock-based compensation	4,553	1,460
Accretion of debt discount and debt issuance costs	0	(197)
Accretion of premiums/discounts on investments, net	(2,875)	(1,477)
Change in fair value of warrant liability	107	(2)
Gain on sale of equipment	(16)	0
(Gain) loss on marketable securities	(5)	22
Change in fair value of investor rights and obligations liability	0	(2,867)
Changes in operating assets and liabilities
Prepaid expenses and other current assets	1,281	(1,253)
Other long-term assets	937	(26)
Accounts payable	763	625
Accrued expenses	(635)	3,199
Operating lease liabilities	38	(779)
Net cash provided by (used in) operating activities	(22,643)	30,053
Investing activities
Purchase of property and equipment	(348)	(105)
Proceeds from sale of equipment	20	0
Purchases of marketable securities	(172,054)	(119,870)
Sales and maturities of marketable securities	112,031	45,377
Net cash used in investing activities	(60,351)	(74,598)
Financing activities
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs	108,211	0
Proceeds from issuance of Series C convertible preferred stock, net of offering costs	0	60,138
Principal payments on debt	0	(3,750)
Proceeds from exercise of stock options	148	109
Net cash provided by financing activities	108,359	56,497
Net increase in cash and cash equivalents	25,365	11,952
Cash and cash equivalents at beginning of period	15,526	5,569
Cash and cash equivalents at end of period	40,891	17,521
Supplemental disclosure of noncash investing and financing activities
Reclassification of warrants from liability to equity	216	0
Reclassification of deferred offering costs paid in prior year to equity	343	0
Conversion of Convertible Preferred Stock to Common Stock [Member]
Supplemental disclosure of noncash investing and financing activities
Conversion of convertible preferred stock to common stock upon initial public offering	$ 192,620	$ 0

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Nature of Operations Contineum Therapeutics, Inc. (the “Company”), is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology indications with high unmet need. The Company, formerly named Sirocco Therapeutics, Inc. (“Sirocco” or “legacy Sirocco”), Inception 3, 2009 October 25, 2011, July 13, 2012. May 2018, May 9, 2017. May 7, 2019, December 31, 2019, January 2020, November 2023, Reverse Stock Split On April 1, 2024, fourth 1 Initial Public Offering On April 9, 2024, April 19, 2024, no In connection with the closing of its IPO, on April 9, 2024, may one Liquidity and Capital Resources Since its inception, the Company has devoted substantially all its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital to support and expand such activities and providing general and administrative support for these operations. The Company incurred a net loss of $10.3 million and $27.7 million for the three nine September 30, 2024 September 30, 2024 September 30, 2024 February 2023 April 2024 As of September 30, 2024 12 As the Company continues to pursue its business plan, it expects to finance its operations through both public and private sales of equity, debt financings or other commercial arrangements, which could include income from collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third no not may third may may may not may Unaudited Interim Condensed Financial Statements The condensed balance sheet as of September 30, 2024 three nine September 30, 2024 2023, nine September 30, 2024 2023, three nine September 30, 2024 not December 31, 2023 December 31, 2023 1, No. 333 278003 424 1933, April 1, 2024 April 4, 2024 (

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. During the nine September 30, 2024, no Basis of presentation The Company has prepared the accompanying condensed financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) and the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. The financial statements are presented in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") promulgated by the Financial Accounting Standards Board ("FASB"). Use of estimates During the nine September 30, 2024, no Recently Issued Accounting Pronouncements In November 2023, No. 2023 07, Segment Reporting (Topic 280 2023 07" 2023 07 December 15, 2023, December 15, 2024, In December 2023, No. 2023 09, Income Taxes (Topic 740 2023 09" 2023 09 December 15, 2024,

Note 3 - Marketable Securities

Note 3 - Marketable Securities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	3. The Company invests its excess cash in marketable securities, including debt securities, commercial paper, asset-backed securities, Yankee debt, certificate of deposit, and U.S. Government agency securities. The following table summarizes the amortized cost and fair value of the Company’s marketable securities by major investment category (in thousands): As of September 30, 2024 Unrealized Maturity in Years Amortized Cost Gains Losses Fair Value U.S. Government agency securities 3 years or less $ 39,743 $ 195 $ (9 ) $ 39,929 Certificate of deposit Less than 1 6,573 15 — 6,588 Corporate debt securities 3 years or less 72,436 247 (5 ) 72,678 Commercial paper Less than 1 37,087 42 (1 ) 37,128 Yankee debt Less than 1 2,131 2 — 2,133 Asset-backed securities 2 years or less 14,487 77 — 14,564 $ 172,457 $ 578 $ (15 ) $ 173,020 As of December 31, 2023 Unrealized Maturity in Years Amortized Cost Gains Losses Fair Value U.S. Government agency securities 2 years or less $ 18,883 $ 11 $ — $ 18,894 Certificate of deposit Less than 1 5,232 13 — 5,245 Corporate debt securities 2 years or less 52,310 65 (6 ) 52,369 Commercial paper Less than 1 28,108 19 (1 ) 28,126 Yankee debt Less than 1 2,445 3 — 2,448 Asset-backed securities 3 years or less 2,576 7 (1 ) 2,582 $ 109,554 $ 118 $ (8 ) $ 109,664 The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, current and expected future economic conditions. The Company has no September 30, 2024 not

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three Level 1 Level 2 not Level 3 no Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands): Fair Value Measurements Using Quoted Prices in Significant Active Markets Significant Other Unobservable for Identical Observable Inputs Total Assets (Level 1) Inputs (Level 2) (Level 3) As of September 30, 2024: Assets: Cash equivalents $ 39,822 $ 39,822 $ — $ — U.S. Government agency securities 39,929 39,929 — — Certificates of deposits 6,588 — 6,588 — Corporate debt securities 72,678 — 72,678 — Commercial paper 37,128 — 37,128 — Yankee debt 2,133 — 2,133 — Asset-backed securities 14,564 — 14,564 — Total financial assets $ 212,842 $ 79,751 $ 133,091 $ — As of December 31, 2023: Assets: Cash equivalents $ 14,646 $ 14,646 $ — $ — U.S. Government agency securities 18,894 16,360 2,534 — Certificates of deposits 5,245 — 5,245 — Corporate debt securities 52,369 — 52,369 — Commercial paper 28,126 — 28,126 — Yankee debt 2,448 — 2,448 — Asset-backed securities 2,582 — 2,582 — Total financial assets $ 124,310 $ 31,006 $ 93,304 $ — Liabilities: Preferred stock warrant liability (109 ) — — (109 ) Total financial liabilities $ (109 ) $ — $ — $ (109 ) The carrying amounts of the Company’s financial instruments, including cash, cash equivalents and marketable securities, prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Included in cash and cash equivalents at September 30, 2024 December 31, 2023 1 Warrant Upon the closing of the IPO, the warrant to purchase shares of Series B preferred stock converted to a warrant to purchase shares of Class A common stock, and upon conversion the warrant met the equity classification requirements and was reclassified to equity. The warrant was remeasured to fair value immediately prior to the conversion to a common stock warrant and the Company recognized changes in the fair value of the warrant liability until April 9, 2024. As of December 31, 2023, 3 The Company’s valuation of the preferred stock warrant as of April 9, 2024 December 31, 2023 3 The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrant. The Company has estimated a 0% dividend yield based on the expected dividend yield and the fact that the Company has never paid or declared dividends. Significant increases or decreases in any of these inputs in isolation would result in a significantly different fair value measurement. An increase in the risk-free interest rate, and/or an increase in the remaining contractual term or expected volatility, and/or an increase in the fair value of the convertible preferred stock would result in an increase in the fair value of the warrant. The following table summarizes the change in fair value of the preferred stock warrant liability, a Level 3 nine September 30, 2024 ( Warrant Liability Balance at December 31, 2023 $ 109 Change in fair value of warrant liability 107 Balance at April 9, 2024 $ 216 Reclassification to equity (216 ) Balance at September 30, 2024 $ —

Note 5 - Accrued Expenses

Note 5 - Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Accrued Expenses [Text Block]	5. Accrued expenses consisted of the following (in thousands): September 30, December 31, 2024 2023 Accrued compensation expenses $ 2,177 $ 1,904 Accrued research and development expenses 1,340 1,546 Accrued professional and consulting expenses 197 834 Other accrued expenses 84 101 Total accrued expenses $ 3,798 $ 4,385

Note 6 - Convertible Preferred

Note 6 - Convertible Preferred Stock and Stockholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Shareholders' Equity and Share-Based Payments [Text Block]	6. Equity (Deficit) Upon the closing of the IPO, the Company’s outstanding convertible preferred stock automatically converted into 9,177,064 shares of Class A common stock and 6,729,172 shares of Class B common stock. Converted preferred stock outstanding as of the date of the IPO consisted of 15,906,236 shares. Each share of outstanding Series A, Series A- 1, one Convertible Preferred Stock As of December 31, 2023, 1, not not not The authorized, issued, and outstanding shares of convertible preferred stock as of December 31, 2023 Shares Authorized Shares Issued and Outstanding Liquidation Preference (in thousands) Series A 1,786,607 1,786,604 $ 10,000 Series A-1 1,429,286 1,423,119 11,179 Series B 3,362,377 3,346,607 32,034 Series C 10,362,324 9,349,906 140,249 16,940,594 15,906,236 $ 193,462 Common Stock The Company has two September 30, 2024 Voting, dividend, and liquidation rights of the holders of the common stock were subject to, and qualified by, the rights, preferences and privileges of the holders of the convertible preferred stock. The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. Class A common stock reserved for future issuance consisted of the following: September 30, December 31, 2024 2023 Convertible preferred stock — 15,906,236 Common stock options granted and outstanding 4,122,230 2,674,405 Shares available for issuance under the 2024 Plan 1,698,056 — Shares available for issuance under the 2012 Plan — 502,491 Preferred stock warrant — 15,764 Common stock warrant 15,764 — Common stock reserved under the 2024 Employee Stock Purchase Plan 280,000 — Total common stock reserved for future issuance 6,116,050 19,098,896 There are no shares of Class B common stock reserved for future issuance as of September 30, 2024 December 31, 2023. Stock Options In March 2024, 2024 "2024 2024 2012 "2012 2012 2024 The number of shares initially reserved for issuance under the 2024 September 30, 2024, 2024 2024 first 2025 2034, Under the 2024 2024 may not not The Company's board of directors (or a committee thereof to which the Company's board of directors has delegated authority) may 2024 2024 not 2024 ten 2024 In March 2024, 2024 "2024 2024 April 9, 2024. 2024 may not As of September 30, 2024, 2024 2024 first 2025 2044, 2024 During the nine September 30, 2024, 2024 not Stock option activity under the 2024 2012 Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Balance at December 31, 2023 2,674,457 $ 5.93 7.14 $ 14,888 Options granted 1,504,382 16.10 — — Options exercised (56,609 ) 2.62 — — Options cancelled and forfeited — — — — Options expired — — — — As of September 30, 2024 4,122,230 $ 9.68 7.59 $ 39,015 Options vested and expected to vest as of September 30, 2024 4,122,230 $ 9.68 7.59 $ 39,015 Options exercisable as of September 30, 2024 2,123,241 $ 4.97 5.93 $ 30,082 The aggregate intrinsic value of options exercised during the three September 30, 2024 2023 not September 30, 2024 September 30, 2024, The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Assumptions: Expected term (in years) 6.08 6.08 6.03 6.08 Expected volatility 112 % 95 % 110 % 94 % Risk free interest rate 3.79 % 4.68 % 4.42 % 4.48 % Dividend yield — — — — The weighted-average grant-date fair value per share of stock options granted during the three nine September 30, 2024 s $16.21 and $ The Company recorded $1.4 million and $0.9 million in stock-based compensation in general and administrative and research and development, respectively, for the three September 30, 2024. three September 30, 2023. The Company recorded $2.6 million and $2.0 million in stock-based compensation in general and administrative and research and development, respectively, for the nine September 30, 2024. nine September 30, 2023. As of September 30, 2024, September 30, 2023,

Note 7 - Income Taxes

Note 7 - Income Taxes	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7 . Income Taxes The Company’s interim income tax provision consists of U.S. federal and state income taxes based on the estimated annual effective tax rate that the Company expects for the full year together with the tax effect of discrete items. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. For the three nine September 30, 2024, not December 31, 2024. As of September 30, 2023, 2023, y 1.96% of ected pre-tax income. The estimated annual tax expense consists of a provision for federal and state income taxes. For the three September 30, 2023, nine September 30, 2023, Under Section 382 383 50% three may 382 February 9, 2021. July 13, 2012, April 29, 2018, March 15, 2019, February 9, 2021, February 9, 2021, 382 not February 9, 2021, may may In assessing the realizability of deferred tax assets, the Company evaluates whether it is more likely than not not not September 30, 2024.

Note 8 - License Agreement

Note 8 - License Agreement	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	8. In February 2023, 307 2 307 may, 307 first 3 307, 3 307, 307. The Company sold approximately 1.7 million shares of series C convertible preferred stock to Johnson & Johnson Innovation - JJDC, Inc., an affiliate of J&J, at $15.00 per share, for an aggregate purchase price of approximately $25.0 million, in April 2023. The Company concluded that J&J represented a customer and applied relevant guidance from ASC 606 second 2023, May 2023 September 30, 2024 In August 2023, 2 307 2 2 no September 30, 2024 no 2 no

Note 9 - Net Loss Per Share

Note 9 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	9. The following table sets forth the computation of the basic and diluted net income (loss) per share (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator, basic: Net income (loss) $ (10,267 ) $ (6,251 ) $ (27,693 ) $ 30,489 Allocation of earnings to participating preferred stockholders — — — 26,149 Net income (loss) applicable to common stockholders $ (10,267 ) $ (6,251 ) $ (27,693 ) $ 4,340 Denominator, basic: Weighted-average common shares issued 25,730,014 2,326,529 17,182,865 2,303,561 Less: weighted-average unvested common stock issued upon early exercise of stock options — (1,941 ) — (5,386 ) Weighted-average shares used to compute net income (loss) per common share, basic 25,730,014 2,324,588 17,182,865 2,298,175 Numerator, diluted: Net income (loss) attributable to common stockholders $ (10,267 ) $ (6,251 ) $ (27,693 ) $ 4,340 Change in fair value of warrant liability — — — (2 ) Change in fair value of put option — — — (2,867 ) Net income (loss) applicable to common stockholders $ (10,267 ) $ (6,251 ) $ (27,693 ) $ 1,471 Denominator, diluted: Weighted-average shares used to compute net income (loss) per common share, diluted 25,730,014 2,324,588 17,182,865 2,298,175 Common stock options — — — 1,024,603 Unvested common stock issued upon early exercise of stock options — — — 5,386 Preferred stock warrant (as converted to common stock) — — — 1,752 Investor rights and obligations — — — 116,062 Weighted-average shares used to compute net income (loss) per common share, diluted 25,730,014 2,324,588 17,182,865 3,445,978 Net income (loss) per share, basic $ (0.40 ) $ (2.69 ) $ (1.61 ) $ 1.89 Net income (loss) per share, diluted $ (0.40 ) $ (2.69 ) $ (1.61 ) $ 0.43 For the three nine September 30, 2024, For the three nine September 30, 2023, no The Company’s potentially dilutive securities, which include convertible preferred stock, common stock options, a common stock warrant, unvested common stock issued upon early exercise of stock options, common stock reserved under the 2024 the three nine September 30, 2024 three September 30, 2023, The following potentially dilutive securities have been excluded from the diluted per share calculation for the periods presented as they would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Convertible preferred stock (as converted to common stock) — 15,906,273 — — Common stock options 4,122,230 2,155,977 4,122,230 954,821 Common stock warrant 15,764 — 15,764 — Unvested common stock issued upon early exercise of stock options — 1,941 — — Common stock reserved under the 2024 ESPP 280,000 — 280,000 — Preferred stock warrant (as converted to common stock) — 15,764 — — 4,417,994 18,079,955 4,417,994 954,821

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2024 shares	Sep. 30, 2024 shares
ecd_TradingArrByIndTable
Material Terms of Trading Arrangement [Text Block]		em 5 From time to time, our officers (as defined in Rule 16a 1 may 10b5 1 10b5 1 408 three September 30, 2024, none Name (Title) Action Taken (Date of Action) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities Carmine Stengone ( President and Chief Executive Officer Adoption ( August 19, 2024 Rule 10b5 1 Sale Until November 19, 2025 Up to 250,980 shares Peter Slover ( Chief Financial Officer Adoption ( August 19, 2024 Rule 10b5 1 Sale Until November 19, 2025 Up to 41,780 shares Daniel Lorrain, Ph.D. ( Chief Scientific Officer Adoption ( August 19, 2024 Rule 10b5 1 Sale Until November 19, 2025 Up to 188,325 shares Stephen Huhn, M.D. ( Chief Medical Officer and Senior Vice President, Clinical Development ) Adoption ( August 19, 2024 Rule 10b5 1 Sale Until November 19, 2025 Up to 47,300 sha John Healy ( General Counsel and Corporate Secretary Adoption ( August 20, 2024 Rule 10b5 1 Sale Until November 19, 2025 Up to 11,328 shares Lori Lyons-Williams ( Director Adoption ( August 21, 2024 Rule 10b5 1 Sale Until November 19, 2025 Up to 11,784 shares * Intended to satisfy the affirmative defense of Rule 10b5 1
Carmine Stengone [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Name	Carmine Stengone
Trading Arrangement, Individual Title	President and Chief Executive Officer
Trading Arrangement Adoption Date	August 19, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	true
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Trading Arrangement Duration	1 year 29 days
Trading Arrangement, Securities Aggregate Available Amount	250,980	250,980
Peter Slover [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Name	Peter Slover
Trading Arrangement, Individual Title	Chief Financial Officer
Trading Arrangement Adoption Date	August 19, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	true
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Trading Arrangement Duration	1 year 29 days
Trading Arrangement, Securities Aggregate Available Amount	41,780	41,780
Daniel Lorrain [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Name	Daniel Lorrain, Ph.D.
Trading Arrangement, Individual Title	Chief Scientific Officer
Trading Arrangement Adoption Date	August 19, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	true
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Trading Arrangement Duration	1 year 29 days
Trading Arrangement, Securities Aggregate Available Amount	188,325	188,325
Stephen Huhn [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Name	Stephen Huhn, M.D.
Trading Arrangement, Individual Title	Chief Medical Officer and Senior Vice President, Clinical Development
Trading Arrangement Adoption Date	August 19, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	true
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Trading Arrangement Duration	1 year 29 days
Trading Arrangement, Securities Aggregate Available Amount	47,300	47,300
John Healy [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Name	John Healy
Trading Arrangement, Individual Title	General Counsel and Corporate Secretary
Trading Arrangement Adoption Date	August 20, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	true
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Trading Arrangement Duration	1 year 29 days
Trading Arrangement, Securities Aggregate Available Amount	11,328	11,328
Lori Lyons-Williams [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Name	Lori Lyons-Williams
Trading Arrangement, Individual Title	Director
Trading Arrangement Adoption Date	August 21, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	true
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Trading Arrangement Duration	1 year 29 days
Trading Arrangement, Securities Aggregate Available Amount	11,784	11,784

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The Company has prepared the accompanying condensed financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) and the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. The financial statements are presented in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") promulgated by the Financial Accounting Standards Board ("FASB").
Use of Estimates, Policy [Policy Text Block]	Use of estimates During the nine September 30, 2024, no
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In November 2023, No. 2023 07, Segment Reporting (Topic 280 2023 07" 2023 07 December 15, 2023, December 15, 2024, In December 2023, No. 2023 09, Income Taxes (Topic 740 2023 09" 2023 09 December 15, 2024,

Note 3 - Marketable Securities

Note 3 - Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]	As of September 30, 2024 Unrealized Maturity in Years Amortized Cost Gains Losses Fair Value U.S. Government agency securities 3 years or less $ 39,743 $ 195 $ (9 ) $ 39,929 Certificate of deposit Less than 1 6,573 15 — 6,588 Corporate debt securities 3 years or less 72,436 247 (5 ) 72,678 Commercial paper Less than 1 37,087 42 (1 ) 37,128 Yankee debt Less than 1 2,131 2 — 2,133 Asset-backed securities 2 years or less 14,487 77 — 14,564 $ 172,457 $ 578 $ (15 ) $ 173,020 As of December 31, 2023 Unrealized Maturity in Years Amortized Cost Gains Losses Fair Value U.S. Government agency securities 2 years or less $ 18,883 $ 11 $ — $ 18,894 Certificate of deposit Less than 1 5,232 13 — 5,245 Corporate debt securities 2 years or less 52,310 65 (6 ) 52,369 Commercial paper Less than 1 28,108 19 (1 ) 28,126 Yankee debt Less than 1 2,445 3 — 2,448 Asset-backed securities 3 years or less 2,576 7 (1 ) 2,582 $ 109,554 $ 118 $ (8 ) $ 109,664

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Quoted Prices in Significant Active Markets Significant Other Unobservable for Identical Observable Inputs Total Assets (Level 1) Inputs (Level 2) (Level 3) As of September 30, 2024: Assets: Cash equivalents $ 39,822 $ 39,822 $ — $ — U.S. Government agency securities 39,929 39,929 — — Certificates of deposits 6,588 — 6,588 — Corporate debt securities 72,678 — 72,678 — Commercial paper 37,128 — 37,128 — Yankee debt 2,133 — 2,133 — Asset-backed securities 14,564 — 14,564 — Total financial assets $ 212,842 $ 79,751 $ 133,091 $ — As of December 31, 2023: Assets: Cash equivalents $ 14,646 $ 14,646 $ — $ — U.S. Government agency securities 18,894 16,360 2,534 — Certificates of deposits 5,245 — 5,245 — Corporate debt securities 52,369 — 52,369 — Commercial paper 28,126 — 28,126 — Yankee debt 2,448 — 2,448 — Asset-backed securities 2,582 — 2,582 — Total financial assets $ 124,310 $ 31,006 $ 93,304 $ — Liabilities: Preferred stock warrant liability (109 ) — — (109 ) Total financial liabilities $ (109 ) $ — $ — $ (109 )
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant Liability Balance at December 31, 2023 $ 109 Change in fair value of warrant liability 107 Balance at April 9, 2024 $ 216 Reclassification to equity (216 ) Balance at September 30, 2024 $ —

Note 5 - Accrued Expenses (Tabl

Note 5 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2024 2023 Accrued compensation expenses $ 2,177 $ 1,904 Accrued research and development expenses 1,340 1,546 Accrued professional and consulting expenses 197 834 Other accrued expenses 84 101 Total accrued expenses $ 3,798 $ 4,385

Note 6 - Convertible Preferre_2

Note 6 - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Convertible Preferred Stock [Table Text Block]	Shares Authorized Shares Issued and Outstanding Liquidation Preference (in thousands) Series A 1,786,607 1,786,604 $ 10,000 Series A-1 1,429,286 1,423,119 11,179 Series B 3,362,377 3,346,607 32,034 Series C 10,362,324 9,349,906 140,249 16,940,594 15,906,236 $ 193,462
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	September 30, December 31, 2024 2023 Convertible preferred stock — 15,906,236 Common stock options granted and outstanding 4,122,230 2,674,405 Shares available for issuance under the 2024 Plan 1,698,056 — Shares available for issuance under the 2012 Plan — 502,491 Preferred stock warrant — 15,764 Common stock warrant 15,764 — Common stock reserved under the 2024 Employee Stock Purchase Plan 280,000 — Total common stock reserved for future issuance 6,116,050 19,098,896
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Balance at December 31, 2023 2,674,457 $ 5.93 7.14 $ 14,888 Options granted 1,504,382 16.10 — — Options exercised (56,609 ) 2.62 — — Options cancelled and forfeited — — — — Options expired — — — — As of September 30, 2024 4,122,230 $ 9.68 7.59 $ 39,015 Options vested and expected to vest as of September 30, 2024 4,122,230 $ 9.68 7.59 $ 39,015 Options exercisable as of September 30, 2024 2,123,241 $ 4.97 5.93 $ 30,082
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Assumptions: Expected term (in years) 6.08 6.08 6.03 6.08 Expected volatility 112 % 95 % 110 % 94 % Risk free interest rate 3.79 % 4.68 % 4.42 % 4.48 % Dividend yield — — — —

Note 9 - Net Loss Per Share (Ta

Note 9 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator, basic: Net income (loss) $ (10,267 ) $ (6,251 ) $ (27,693 ) $ 30,489 Allocation of earnings to participating preferred stockholders — — — 26,149 Net income (loss) applicable to common stockholders $ (10,267 ) $ (6,251 ) $ (27,693 ) $ 4,340 Denominator, basic: Weighted-average common shares issued 25,730,014 2,326,529 17,182,865 2,303,561 Less: weighted-average unvested common stock issued upon early exercise of stock options — (1,941 ) — (5,386 ) Weighted-average shares used to compute net income (loss) per common share, basic 25,730,014 2,324,588 17,182,865 2,298,175 Numerator, diluted: Net income (loss) attributable to common stockholders $ (10,267 ) $ (6,251 ) $ (27,693 ) $ 4,340 Change in fair value of warrant liability — — — (2 ) Change in fair value of put option — — — (2,867 ) Net income (loss) applicable to common stockholders $ (10,267 ) $ (6,251 ) $ (27,693 ) $ 1,471 Denominator, diluted: Weighted-average shares used to compute net income (loss) per common share, diluted 25,730,014 2,324,588 17,182,865 2,298,175 Common stock options — — — 1,024,603 Unvested common stock issued upon early exercise of stock options — — — 5,386 Preferred stock warrant (as converted to common stock) — — — 1,752 Investor rights and obligations — — — 116,062 Weighted-average shares used to compute net income (loss) per common share, diluted 25,730,014 2,324,588 17,182,865 3,445,978 Net income (loss) per share, basic $ (0.40 ) $ (2.69 ) $ (1.61 ) $ 1.89 Net income (loss) per share, diluted $ (0.40 ) $ (2.69 ) $ (1.61 ) $ 0.43
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Convertible preferred stock (as converted to common stock) — 15,906,273 — — Common stock options 4,122,230 2,155,977 4,122,230 954,821 Common stock warrant 15,764 — 15,764 — Unvested common stock issued upon early exercise of stock options — 1,941 — — Common stock reserved under the 2024 ESPP 280,000 — 280,000 — Preferred stock warrant (as converted to common stock) — 15,764 — — 4,417,994 18,079,955 4,417,994 954,821

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual) $ / shares in Units, $ in Thousands					3 Months Ended						9 Months Ended
	Apr. 19, 2024 shares	Apr. 19, 2024 USD ($)	Apr. 05, 2024 $ / shares shares	Apr. 01, 2024	Sep. 30, 2024 USD ($) shares	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Apr. 09, 2024 shares	Dec. 31, 2023 USD ($) shares
Proceeds from Issuance of Common Stock | $											$ 108,211	$ 0
Temporary Equity, Shares Outstanding (in shares)					0						0		15,906,236	15,906,236
Common Stock, Shares Authorized (in shares)													220,000,000
Preferred Stock, Shares Authorized (in shares)					10,000,000						10,000,000		10,000,000	0
Net Income (Loss) Attributable to Parent | $					$ (10,267)	$ (9,009)	$ (8,417)	$ (6,251)	$ 41,564	$ (4,824)	$ (27,693)	$ 30,489
Retained Earnings (Accumulated Deficit) | $					(102,837)						(102,837)			$ (75,144)
Cash, Cash Equivalents, and Short-Term Investments | $					$ 213,900						$ 213,900
Common Class A [Member]
Common Stock, Shares Authorized (in shares)					200,000,000						200,000,000		200,000,000	39,630,511
Common Class B [Member]
Common Stock, Shares Authorized (in shares)					20,000,000						20,000,000		20,000,000	0
IPO [Member]
Stock Issued During Period, Shares, New Issues (in shares)			6,875,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 16
Proceeds from Issuance of Common Stock | $		$ 107,900
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	548,682
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				5.5972

Note 3 - Marketable Securitie_2

Note 3 - Marketable Securities (Details Textual) $ in Thousands	Sep. 30, 2024 USD ($)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$ 0

Note 3 - Marketable Securitie_3

Note 3 - Marketable Securities - Amortized Costs and Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Securities, Amortized cost	$ 172,457	$ 109,554
Securities, Gains	578	118
Securities, Losses	(15)	(8)
Securities, Fair Value	173,020	109,664
US Government Agencies Debt Securities [Member]
Securities, Amortized cost	39,743	18,883
Securities, Gains	195	11
Securities, Losses	(9)	0
Securities, Fair Value	39,929	18,894
Certificates of Deposit [Member]
Securities, Amortized cost	6,573	5,232
Securities, Gains	15	13
Securities, Losses	0	0
Securities, Fair Value	6,588	5,245
Corporate Debt Securities [Member]
Securities, Amortized cost	72,436	52,310
Securities, Gains	247	65
Securities, Losses	(5)	(6)
Securities, Fair Value	72,678	52,369
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Securities, Amortized cost	37,087	28,108
Securities, Gains	42	19
Securities, Losses	(1)	(1)
Securities, Fair Value	37,128	28,126
Debt Security, Government, Non-US [Member]
Securities, Amortized cost	2,131	2,445
Securities, Gains	2	3
Securities, Losses	0	0
Securities, Fair Value	2,133	2,448
Asset-Backed Securities [Member]
Securities, Amortized cost	14,487	2,576
Securities, Gains	77	7
Securities, Losses	0	(1)
Securities, Fair Value	$ 14,564	$ 2,582

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) Pure in Thousands, $ in Thousands	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Cash and Cash Equivalents, at Carrying Value	$ 40,891	$ 15,526
Preferred Stock Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0
Money Market Funds [Member]
Cash and Cash Equivalents, at Carrying Value	$ 10,800	$ 11,800

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Securities, fair value	$ 173,020	$ 109,664
US Government Agencies Debt Securities [Member]
Securities, fair value	39,929	18,894
Certificates of Deposit [Member]
Securities, fair value	6,588	5,245
Corporate Debt Securities [Member]
Securities, fair value	72,678	52,369
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Securities, fair value	37,128	28,126
Debt Security, Government, Non-US [Member]
Securities, fair value	2,133	2,448
Asset-Backed Securities [Member]
Securities, fair value	14,564	2,582
Fair Value, Recurring [Member]
Cash equivalents	39,822	14,646
Total financial assets	212,842	124,310
Preferred stock warrant liability		(109)
Total financial liabilities		(109)
Fair Value, Recurring [Member] | US Government Agencies Debt Securities [Member]
Securities, fair value	39,929	18,894
Fair Value, Recurring [Member] | Certificates of Deposit [Member]
Securities, fair value	6,588	5,245
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Securities, fair value	72,678	52,369
Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Securities, fair value	37,128	28,126
Fair Value, Recurring [Member] | Debt Security, Government, Non-US [Member]
Securities, fair value	2,133	2,448
Fair Value, Recurring [Member] | Asset-Backed Securities [Member]
Securities, fair value	14,564	2,582
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	39,822	14,646
Total financial assets	79,751	31,006
Preferred stock warrant liability		0
Total financial liabilities		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]
Securities, fair value	39,929	16,360
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Debt Security, Government, Non-US [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-Backed Securities [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents	0	0
Total financial assets	133,091	93,304
Preferred stock warrant liability		0
Total financial liabilities		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Securities, fair value	0	2,534
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Securities, fair value	6,588	5,245
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Securities, fair value	72,678	52,369
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Securities, fair value	37,128	28,126
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Debt Security, Government, Non-US [Member]
Securities, fair value	2,133	2,448
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-Backed Securities [Member]
Securities, fair value	14,564	2,582
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents	0	0
Total financial assets	0	0
Preferred stock warrant liability		(109)
Total financial liabilities		(109)
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Debt Security, Government, Non-US [Member]
Securities, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-Backed Securities [Member]
Securities, fair value	$ 0	$ 0

Note 4 - Fair Value Measureme_5

Note 4 - Fair Value Measurements - Roll-forward of Level 3 Financial Instruments (Details) - Preferred Stock Warrant Liability [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Apr. 05, 2024	Sep. 30, 2024
Beginning balance	$ 109	$ 216
Change in fair value of warrant liability	107
Reclassification to equity		(216)
Balance at April 9, 2024	$ 216	$ 0

Note 5 - Accrued Expenses - Sch

Note 5 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accrued compensation expenses	$ 2,177	$ 1,904
Accrued research and development expenses	1,340	1,546
Accrued professional and consulting expenses	197	834
Other accrued expenses	84	101
Total accrued expenses	$ 3,798	$ 4,385

Note 6 - Convertible Preferre_3

Note 6 - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details Textual) $ / shares in Units, $ in Millions		1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 09, 2024 shares	Mar. 31, 2024	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Jan. 01, 2024 shares	Dec. 31, 2023 shares
Temporary Equity, Shares Outstanding (in shares)	15,906,236		0		0			15,906,236
Common Stock, Shares Authorized (in shares)	220,000,000
Common Stock, Capital Shares Reserved for Future Issuance (in shares)			6,116,050		6,116,050			19,098,896
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value | $			$ 0.2	$ 0.4
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)			2,123,241		2,123,241
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Available for Early Exercise, Number (in shares)			83,161		83,161
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares			$ 16.21		$ 13.63
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $			$ 22.6	2.8	$ 22.6	$ 2.8
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					3 years 1 month 6 days	10 months 24 days
2024 Employee Stock Purchase Plan (the "2024 ESPP") [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)			280,000		280,000
Employee Stock Ownership Plan, Increase in Reserved Shares, Maximum (in shares)	280,000
Employee Stock Ownership Plan, Increase in Reserved Shares, Percentage of Outstanding Stock	1%
Employee Stock Ownership Plan (ESOP), Shares Contributed to ESOP (in shares)					0
Minimum [Member] | 2024 Employee Stock Purchase Plan (the "2024 ESPP") [Member]
Employee Stock Ownership Plan, Percentage of Compensation	1%
Maximum [Member] | 2024 Employee Stock Purchase Plan (the "2024 ESPP") [Member]
Employee Stock Ownership Plan, Percentage of Compensation	15%
Share-Based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)			4,122,230		4,122,230			2,674,405
Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense | $			$ 1.4	0.3	$ 2.6	$ 0.8
Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense | $			$ 0.9	$ 0.2	$ 2	$ 0.7
The 2024 Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)			1,698,056		1,698,056		2,700,000	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Yearly Increase in Authorized Shares, Percent of Shares Outstanding		5%
The 2024 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
The 2024 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent		100%
Common Class A [Member]
Common Stock, Number of Votes			1		1
Common Stock, Shares Authorized (in shares)	200,000,000		200,000,000		200,000,000			39,630,511
Common Stock, Shares, Outstanding (in shares)			19,006,904		19,006,904			2,349,554
Common Stock, Shares, Issued (in shares)			19,006,904		19,006,904			2,349,554
Common Class B [Member]
Common Stock, Number of Votes			0		0
Common Stock, Shares Authorized (in shares)	20,000,000		20,000,000		20,000,000			0
Common Stock, Shares, Outstanding (in shares)			6,729,172		6,729,172			0
Common Stock, Capital Shares Reserved for Future Issuance (in shares)			0		0
Common Stock, Shares, Issued (in shares)			6,729,172		6,729,172			0
Conversion of Convertible Preferred Stock to Class A Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)	9,177,064
Conversion of Convertible Preferred Stock to Class B Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)	6,729,172

Note 6 - Convertible Preferre_4

Note 6 - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Preferred Stock Shares (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Apr. 09, 2024	Dec. 31, 2023
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000	0
Preferred stock, shares issued (in shares)	0		0
Series A Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	1,786,607
Preferred stock, shares issued (in shares)	1,786,604
Liquidation preference	$ 10,000
Series A-1 Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	1,429,286
Preferred stock, shares issued (in shares)	1,423,119
Liquidation preference	$ 11,179
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	3,362,377
Preferred stock, shares issued (in shares)	3,346,607
Liquidation preference	$ 32,034
Series C Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	10,362,324
Preferred stock, shares issued (in shares)	9,349,906
Liquidation preference	$ 140,249
Convertible Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	16,940,594
Preferred stock, shares issued (in shares)	15,906,236
Liquidation preference	$ 193,462

Note 6 - Convertible Preferre_5

Note 6 - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Common Stock Reserved for Future Issuance (Details) - shares	Sep. 30, 2024	Jan. 01, 2024	Dec. 31, 2023
Total common stock reserved for future issuance (in shares)	6,116,050		19,098,896
Preferred Stock Warrant [Member]
Total common stock reserved for future issuance (in shares)	0		15,764
Common Stock Warrant [Member]
Total common stock reserved for future issuance (in shares)	15,764		0
The 2024 Equity Incentive Plan [Member]
Total common stock reserved for future issuance (in shares)	1,698,056	2,700,000	0
The 2012 Equity Incentive Plan [Member]
Total common stock reserved for future issuance (in shares)	0		502,491
2024 Employee Stock Purchase Plan (the "2024 ESPP") [Member]
Total common stock reserved for future issuance (in shares)	280,000		0
Share-Based Payment Arrangement, Option [Member]
Total common stock reserved for future issuance (in shares)	4,122,230		2,674,405
Convertible Preferred Stock [Member]
Total common stock reserved for future issuance (in shares)	0		15,906,236

Note 6 - Convertible Preferre_6

Note 6 - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Stock Option Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Beginning balance, options (in shares) | shares	2,674,457
Beginning balance, weighted average exercise price (in dollars per share) | $ / shares	$ 5.93
Weighted-average remaining contractual term (Year)	7 years 7 months 2 days	7 years 1 month 20 days
Aggregate intrinsic value | $	$ 39,015	$ 14,888
Options granted (in shares) | shares	1,504,382
Options granted, weighted average exercise price (in dollars per share) | $ / shares	$ 16.1
Options exercised (in shares) | shares	(56,609)
Options exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 2.62
Options cancelled and forfeited (in shares) | shares	0
Options cancelled and forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Options expired (in shares) | shares	0
Options expired, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Ending balance, options (in shares) | shares	4,122,230	2,674,457
Ending balance, weighted average exercise price (in dollars per share) | $ / shares	$ 9.68	$ 5.93
Options Vested and Expected to Vest, options (in shares) | shares	4,122,230
Options Vested and Expected to Vest, weighted average exercise price (in dollars per share) | $ / shares	$ 9.68
Options Vested and Expected to Vest, Weighted-average remaining contractual term (Year)	7 years 7 months 2 days
Options Vested and Expected to Vest, Aggregate intrinsic value | $	$ 39,015
Options Exercisable, options (in shares) | shares	2,123,241
Options Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 4.97
Options Exercisable, Weighted-average remaining contractual term (Year)	5 years 11 months 4 days
Options Exercisable, Aggregate intrinsic value | $	$ 30,082

Note 6 - Convertible Preferre_7

Note 6 - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Weighted-average Assumptions (Details) - Share-Based Payment Arrangement, Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Expected term (in years) (Year)	6 years 29 days	6 years 29 days	6 years 10 days	6 years 29 days
Expected volatility	112%	95%	110%	94%
Risk free interest rate	3.79%	4.68%	4.42%	4.48%
Dividend yield	0%	0%	0%	0%

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Effective Income Tax Rate Reconciliation, Percent				1.96%
Income Tax Expense (Benefit)	$ 0	$ (118)	$ 0	$ 611
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (10,267)	$ (6,369)	$ (27,693)	$ 31,100

Note 8 - License Agreement (Det

Note 8 - License Agreement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended			3 Months Ended
	May 31, 2023	Apr. 30, 2023	Feb. 28, 2023	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023
Stock Issued During Period, Value, New Issues				$ 107,867	$ 0	$ 0
Preferred Stock Purchase Agreement [Member] | JJDC [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1.7
Shares Issued, Price Per Share (in dollars per share)		$ 15
Stock Issued During Period, Value, New Issues		$ 25,000
J&J License Agreement [Member]
Upfront Payment Received			$ 50,000
Contract with Customer, Asset, after Allowance for Credit Loss			$ 1,000,000
Revenue Not from Contract with Customer	$ 50,000

Note 9 - Net Loss Per Share - C

Note 9 - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended						9 Months Ended
		Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Income (Loss) Attributable to Parent		$ (10,267)	$ (9,009)	$ (8,417)	$ (6,251)	$ 41,564	$ (4,824)	$ (27,693)	$ 30,489
Allocation of earnings to participating preferred stockholders		0			0			0	26,149
Net income (loss) applicable to common stockholders		$ (10,267)			$ (6,251)			$ (27,693)	$ 4,340
Weighted-average common shares issued (in shares)		25,730,014			2,326,529			17,182,865	2,303,561
Less: weighted-average unvested common stock issued upon early exercise of stock options (in shares)		0			(1,941)			0	(5,386)
Weighted-average shares used to compute net income (loss) per common share, basic (in shares)		25,730,014			2,324,588			17,182,865	2,298,175
Change in fair value of warrant liability		$ 0			$ 0			$ 0	$ (2)
Change in fair value of put option		0			0			0	(2,867)
Net income (loss) applicable to common stockholders		$ (10,267)			$ (6,251)			$ (27,693)	$ 1,471
Common stock options (in shares)		0			0			0	1,024,603
Unvested common stock issued upon early exercise of stock options (in shares)		0			0			0	5,386
Preferred stock warrant (as converted to common stock) (in shares)		0			0			0	1,752
Investor rights and obligations (in shares)		0			0			0	116,062
Weighted-average shares used to compute net income (loss) per common share, diluted (in shares)		25,730,014			2,324,588			17,182,865	3,445,978
Net income (loss) per share, basic (in dollars per share)	[1]	$ (0.4)			$ (2.69)			$ (1.61)	$ 1.89
Net income (loss) per share, diluted (in dollars per share)	[1]	$ (0.4)			$ (2.69)			$ (1.61)	$ 0.43
[1]Basic and diluted per share amounts are the same for Class A and Class B shares.

Note 9 - Net Loss Per Share - A

Note 9 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive securities (in shares)	4,417,994	18,079,955	4,417,994	954,821
Convertible Preferred Stock [Member]
Antidilutive securities (in shares)	0	15,906,273	0	0
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	4,122,230	2,155,977	4,122,230	954,821
Common Stock Warrant [Member]
Antidilutive securities (in shares)	15,764	0	15,764	0
Unvested Common Stock Issued Upon Early Exercise of Stock Options [Member]
Antidilutive securities (in shares)	0	1,941	0	0
2024 Employee Stock Purchase Plan (the "2024 ESPP") [Member]
Antidilutive securities (in shares)	280,000	0	280,000	0
Preferred Stock Warrant [Member]
Antidilutive securities (in shares)	0	15,764	0	0